Over the last 12 months, RAPT Therapeuticss shares have ranged in value from as little as 14.89 up to 43.26. RAPT Therapeutics share price volatility. Systematic retrieval of data or other content from, whether to create or compile, post to other websites, directly or indirectly, as text, video or audio, a collection, compilation, database or directory, is prohibited absent our express prior written consent. Were not expecting RAPT Therapeutics to pay a dividend over the next 12 months. The best long-term & short-term RAPT Therapeutics share price.
#Rapt therapeutics stock trial#
Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. RAPT Therapeutics (NASDAQ:RAPT) slumps 25 premarket despite positive initial data from its ongoing Phase 1/2 trial for FLX475 in multiple cancer indications. RAPT Therapeutics Stock Forecast, RAPT stock price prediction.
A Look Into Healthcare Sector Value Stocks Benzinga Insights.
You may use and the contents contained in solely for your own individual non-commercial and informational purposes only. RAPT Therapeutics 13G Filing From Perceptive Advisors Shows New 5.4 Stake In Co. Liable for your own investment decisions and agree to the (NASDAQ:RAPT) stock with an Outperform rating and a price target of 49. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. In August, investment advisory SVB Leerink initiated coverage of RAPT Therapeutics, Inc. Users should not base their investment decision upon . is a clinical-stage immunology-based biopharmaceutical company. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Stock information is delayed approximately 15 minutes. The stock information and stock charts are provided by West LLC., a third party service, and RAPT Therapeutics does not maintain or provide information directly to this service. was incorporated in 2015 and is headquartered in South San Francisco, is a research service that provides financial data and technical analysis of publicly traded stocks.Īll users should speak with their financial advisor before buying or selling any securities. Stock analysis for RAPT Therapeutics Inc (RAPT:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The stock information provided is for informational purposes only and is not intended for trading purposes. and changed its name to RAPT Therapeutics, Inc. The huge gain came after the company announced positive top-line results. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. RAPT Therapeutics ( NASDAQ:RAPT) stock was crushing it on Monday, with shares skyrocketing 110.4 as of 11:59 a.m. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. (RAPT) stock quote, history, news and other vital information to help you with your stock trading and investing. The shares were sold at an average price of 40.00, for a total transaction of 80,000.00. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. (NASDAQ:RAPT) insider William Ho sold 2,000 shares of the stock in a transaction dated Wednesday, January 5th.
0 kommentar(er)
